Table 1

Characteristics of the studies included in the meta-analysis (n=54 studies)

Last name of the first author, year	Polymorphic gene	Study design	Ethnicity	Sample size (case/control)	Age (years) (case/control)*	Male (%) (case/control)	Anti-TB drug regimen administered	Diagnostic criteria of ATDILI	Quality score†
Feng et al, 201423	CYP2E1	Case-control	Chinese	173/173	48.8/48.6	68.0/68.0	INH, RIF, PZA	ALT>3 × ULN	6
Kim et al, 200948	CYP2E1	Case-control	Korean	67/159	42.1/42.8	65.7/65.4	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Singh et al, 201449	CYP2E1	Cohort	Indian	50/135	NA/NA	NA/NA	NA	ALT>2 × ULN	7
Tang et al, 201350	CYP2E1	Case-control	Chinese	89/356	43.7/43.6	73.0/73.0	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Ben Mahmoud et al, 201251	NAT2	Cohort	Tunisian	14/52	42.4/42.1	42.8/48.1	INH, RIF containing regimen	ALT>2 × ULN	7
Bozok Cetintaş et al, 200852	NAT2	Case-control	Turkish	30/70	39.8/37.3	50.0/72.8	INH, RIF, PZA, EMB	ALT>3 × ULN	6
Higuchi et al, 200753	NAT2	Cohort	Japanese	18/82	60.8/64.7	50.0/57.3	INH, RIF containing regimen	ALT>2 × ULN	7
Ho et al, 201354	NAT2	Cohort	Taiwanese	20/328	NA/NA	NA/NA	INH, RIF, PZA, EMB	ALT>5 × ULN	6
Huang et al, 200255	NAT2	Cohort	Taiwanese	33/191	73.3/63.7	87.9/88.5	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Khalili et al, 201156	NAT2	Case-control	Iranian	14/36	NA/NA	NA/NA	INH, RIF, PZA, EMB	ALT>3 × ULN	6
Leiro-Fernandez et al, 201157	NAT2	Case-control	Caucasian	50/67	34.0/30.5‡	54.0/56.7	INH, RIF, PZA	ALT>3 × ULN	7
Lv et al, 201224	NAT2	Case-control	Chinese	89/356	42.0/42.0‡	73.0/73.0	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Ng et al, 201458	NAT2	Case-control	Mixed	26/101	48.3/NA	38.5/NA	INH containing regimen	ALT>5 × ULN	7
Ohno et al, 200059	NAT2	Cohort	Japanese	14/63	NA/NA	NA/NA	INH, RIF	ALT>1.5 × ULN	7
Possuelo et al, 200860	NAT2	Cohort	Brazilian	14/240	38.9/36.5	50.0/66.9	INH, RIF, PZA	ALT>3 × ULN	7
Rana et al, 201261	NAT2	Cohort	Indian	50/201	45.3/43.8	76.0/57.2	INH, RIF, PZA, EMB	ALT>5 × ULN	7
Shimizu et al, 200662	NAT2	Case-control	Japanese	10/32	60.5/64.9	70.0/46.9	INH, RIF	ALT>2 × ULN	6
Yuliwulandari et al, 201663	NAT2	Case-control	Indonesian	50/191	NA/NA	NA/NA	NA	ALT>2 × ULN	7
Wattanapokayakit et al, 201625	NAT2	Case-control	Thailand	53/85	51.4/50.2	58.5/60.0	INH containing regimen	ALT>2 × ULN	7
Chatterjee et al, 201064	GSTM1, GSTT1	Case-control	Indian	51/100	37.2/33.2	49.0/63.0	INH, RIF, PZA	ALT>3 × ULN	7
Gupta et al, 201365	GSTM1, GSTT1	Cohort	Indian	50/246	37.0/36.5‡	48.0/56.5	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Huang et al, 200766	GSTM1, GSTT1	Case-control	Taiwanese	63/63	62.0/NA	NA/NA	NA	ALT>5 × ULN	6
Kim et al, 201067	GSTM1, GSTT1	Case-control	Korean	57/190	47.3/42.4	59.6/67.9	INH, RIF, PZA, EMB	ALT>3 × ULN	7
Leiro et al, 200868	GSTM1, GSTT1	Case-control	Caucasian	35/60	34.0/31.0‡	40.0/41.7	INH, RIF, PZA	ALT>3 × ULN	7
Liu et al, 201469	GSTM1, GSTT1	Case-control	Chinese	20/143	35.9/61.2	60.0/59.4	INH containing regimen	ALT>2 × ULN	7
Monteiro et al, 201270	GSTM1, GSTT1	Cohort	Brazilian	59/118	37.0/38.0‡	76.0/61.0	NA	ALT>2 × ULN	7
Rana et al, 201371	GSTM1, GSTT1	Cohort	Indian	30/220	43.6/42.3	60.0/64.5	INH, RIF	ALT>5 × ULN	6
Roy et al, 200172	GSTM1, GSTT1	Case-control	Indian	33/33	NA/NA	NA/NA	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Chen et al, 201542	SLCO1B1	Case-control	Chinese	89/356	43.7/43.6	73.0/73.0	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Kim et al, 201210	SLCO1B1	Case-control	Korean	67/159	43.0/42.8	65.7/65.4	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Li et al, 201228	SLCO1B1	Case-control	Chinese	118/155	40.5/39.3	48.3/54.8	RIF	ALT>3 × ULN	7
An et al, 201273	NAT2, CYP2E1	Case-control	Chinese	101/107	36.0/33.4‡	55.0/70.0	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Bose et al, 201174	NAT2, CYP2E1	Cohort	Indian	41/177	38.0/36.0	43.9/47.4	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Chamorro et al, 201375	NAT2, CYP2E1	Cohort	Mixed (South American)	47/128	29.0/27.0	41.3/64.8	INH, RIF, PZA, EMB	ALT>3 × ULN	7
Cho et al, 200776	NAT2, CYP2E1	Cohort	Korean	18/114	51.2/46.7	66.7/55.3	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Gupta et al, 201327	NAT2, CYP2E1	Case-control	Indian	50/165	37.0/38.0	48.0/60.0	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Huang et al, 200377	NAT2, CYP2E1	Cohort	Taiwanese	49/269	70.0/59.0‡	18.4/14.9	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Lee et al, 201078	NAT2, CYP2E1	Cohort	Taiwanese	45/95	58.4/54.9	60.0/66.3	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Mishra et al, 201379	NAT2, CYP2E1	Case-control	Indian	33/173	38.0/NA	52.0/NA	INH, RIF, PZA, EMB	ALT>3 × ULN	7
Santos et al, 201380	NAT2, CYP2E1	Case-control	Brazilian	18/252	47.7/45.6	56.0/49.0	INH, RIF	ALT>3 × ULN	7
Vuilleumier et al, 200681	NAT2, CYP2E1	Case-control	Mixed	8/63	27–35: 2/22§ >36: 5/18§	38.0/51.0	INH	AST or ALT>4 × ULN	7
Yamada et al, 200982	NAT2, CYP2E1	Case-control	Mixed	23/147	NA/NA	13.0/42.9	INH	ALT>2 × ULN	7
Zaverucha-do-Valle et al, 201483	NAT2, CYP2E1	Cohort	Brazilian	50/79	<40: 28/43§ >40: 20/36§	60.4/72.2	INH, RIF, PZA	ALT>2 × ULN	6
Sharma et al, 201484	CYP2E1, GSTM1	Cohort	Indian	105/185	35.2/27.6	55.7/72.1	INH, RIF, PZA, EMB	ALT>5 × ULN	7
Wang et al, 201085	CYP2E1, GSTM1	Case-control	Chinese	104/111	48.6/44.7	67.3/67.6	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Tang et al, 201286	CYP2E1, GSTM1, GSTT1	Case-control	Chinese	89/356	43.7/43.6	73.0/73.0	INH, RIF, PZA, EMB	ALT>2 × ULN	7
Yimer et al, 201145	NAT2, SLCO1B1	Cohort	Ethiopian	41/160	NA/NA	NA/NA	INH, RIF, PZA, EMB	ALT>2 × ULN	6
Brito et al, 201487	NAT2, CYP2E1, GSTM1, GSTT1	Cohort	Brazilian	15/230	38.1/36.8	46.7/NA	INH, RIF, PZA	ALT>3 × ULN	7
Forestiero et al, 201388	NAT2, CYP2E1, GSTM1, GSTT1	Cohort	Brazilian	59/40	NA/NA	49.2/60.0	INH, RIF, PZA	ALT>2.5 × ULN	6
Rana et al, 201489	NAT2, CYP2E1, GSTM1, GSTT1	Cohort	Indian	55/245	43.6/42.3	60.0/62.0	INH, RIF, PZA, EMB	ALT>5 × ULN	6
Singla et al, 201426	NAT2, CYP2E1, GSTM1, GSTT1	Case-control	Indian	17/391	48.2/32.7	64.7/61.4	INH, RIF, PZA, EMB, STM	ALT>2 × ULN	7
Sotsuka et al, 201190	NAT2, CYP2E1, GSTM1, GSTT1	Case-control	Japanese	20/92	54.9/50.4	90.0/73.9	INH, RIF, PZA, EMB or STM	ALT>3 × ULN	7
Teixeira et al, 201191	NAT2, CYP2E1, GSTM1, GSTT1	Case-control	Brazilian	26/141	47.6/43.0	61.5/52.5	INH containing regimen	ALT>3 × ULN	7
Xiang et al, 201492	NAT2, CYP2E1, GSTM1, GSTT1	Cohort	Chinese	89/2155	37.0/44.5	67.4/55.7	INH, RIF, PZA, EMB	ALT>2 × ULN	7

*Mean unless otherwise stated.
†Detailed scoring for each quality assessment criterion based on the revised Little’s recommendation in online supplementary table S2.
‡Median age.
§Number of individuals in the age ranges.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ATDILI, anti-tuberculosis drug-induced liver injury; CYP2E1, cytochrome P450 2E1; EMB, ethambutol; GSTM1, glutathione S-transferase Mu 1; GSTT1, glutathione S-transferase Theta 1; INH, isoniazid; NA, not available; NAT2, N-acetyltransferase 2; PZA, pyrazinamide; RIF, rifampicin; SLCO1B1, solute carrier organic anion transporter family member 1B1 (encoding organic anion transporting polypeptide 1B1 (OATP1B1)); STM, streptomycin; TB, tuberculosis; ULN, upper limit of normal.